ALX Oncology
ALXO
105 hedge funds and large institutions have $510M invested in ALX Oncology in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 9 closing their positions.
295% more call options, than puts
Call options by funds: $1.58M | Put options by funds: $400K
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
13% more funds holding
Funds holding: 93 → 105 (+12)
0.58% less ownership
Funds ownership: 91.86% → 91.28% (-0.58%)
2% less capital inflows, than outflows
Capital inflows: $37.9M | Capital outflows: $38.8M
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
+$13.4M |
| 2 |
Redmile Group
San Francisco,
California
|
+$9.37M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.54M |
| 4 |
Squarepoint
New York
|
+$1.49M |
| 5 |
Goldman Sachs
New York
|
+$931K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.74M |
| 3 |
OrbiMed
New York
|
-$5.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.36M |
| 5 |
Schonfeld Strategic Advisors
New York
|
-$1.56M |
ALXO Hedge Fund Activity: Q1 2024 in Review
105 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2024, worth a combined $510M — down 25% from $681M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ALXO positions and 9 closed out — a net gain of 12 holders — while 27 added to existing stakes and 31 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $13.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $13.6M sold.
- 105 institutional investors held ALX Oncology (ALXO) as of Q1 2024, up from 93 in Q4 2023.
- Funds reported $510M of ALX Oncology stock for Q1 2024, down 25% quarter-over-quarter.
- 21 funds opened new ALX Oncology positions in Q1 2024 and 9 closed out, a net change of +12 holders.
- The largest ALX Oncology buyer in Q1 2024 was Vestal Point Capital, an estimated $13.4M added.
- The largest ALX Oncology seller in Q1 2024 was Point72 Asset Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2024.